Swine Vesicular Disease Virus

Overview and Taxonomy of Swine Vesicular Disease Virus

Swine vesicular disease virus (SVDV) is a highly significant pathogen of swine, primarily due to its clinical and economic impact on the global pig industry. The disease it causes, swine vesicular disease (SVD), is clinically indistinguishable from foot-and-mouth disease (FMD) and other vesicular conditions, posing a constant challenge to veterinary surveillance and international trade [1, 3]. As a notifiable disease under the Terrestrial Animal Health Code of the World Organisation for Animal Health (WOAH), the accurate and rapid identification of SVDV is paramount for maintaining the integrity of FMD-free zones and facilitating the safe movement of live pigs and porcine products across borders. The virus itself is a classic member of the Picornaviridae family, characterized by its small size, non-enveloped virion, and a single-stranded, positive-sense RNA genome [8]. Due to its close genetic and antigenic relationship with human viruses, its evolutionary biology offers a fascinating case study in cross-species transmission and viral adaptation.

Taxonomic Classification and Phylogenetic Position

The taxonomic hierarchy of SVDV places it firmly within the order Picornavirales, family Picornaviridae. It is a recognized member of the species Enterovirus B within the genus Enterovirus [8, 9, 12]. This classification is critically important as Enterovirus B is a large group that includes numerous human pathogens, most notably the group B coxsackieviruses (CV-B). Indeed, SVDV is not a distantly related animal virus; it is, in fact, a porcine-adapted variant of human coxsackievirus B5 (CV-B5) [7, 9]. This anthropogenic origin is a defining feature of SVDV's taxonomy and explains many of its biological properties. Phylogenetic analyses of the VP1 capsid protein gene, a standard locus for enterovirus typing, have illuminated the evolutionary history of the virus. Studies have delineated three distinct SVDV genotypes (I, II, and III), which evolved sequentially over time, with some temporal overlap [7]. This genotypic structure reflects the virus’s ongoing evolution since its emergence in pigs.

The genetic relationship between SVDV and CV-B5 is so close that it challenges the traditional definition of a virus species. Spatiotemporal phylodynamics have demonstrated that the major hubs of CV-B5 transmission are in human populations in China, whereas the major hubs of SVDV are in pig populations in Italy [7]. This geographic segregation is a direct consequence of a host-switching event, where a human CV-B5 strain successfully crossed into the swine population, likely during the mid-20th century [9]. This single, recent, and anthroponotic origin is supported by comprehensive genomic analyses, which show that all circulating SVDV strains share a common ancestor that emerged from a human CV-B5 lineage [9]. This has profound implications for disease surveillance, as it implies that the potential for future zoonotic or reverse-zoonotic events exists, though SVDV itself is not considered a zoonotic threat in its current porcine-adapted form.

Molecular Basis of Taxonomy and Pathogenesis

The close relationship between SVDV and CV-B5 is underpinned by shared molecular characteristics, particularly in receptor usage. The coxsackievirus-adenovirus receptor (CAR) is a primary functional receptor for all six serotypes of group B coxsackieviruses and, critically, for SVDV as well [11]. Studies have demonstrated that Chinese hamster ovary (CHO) cells expressing human CAR become susceptible to SVDV infection, producing high titers of progeny virus, while mock-transfected cells remain resistant. This dependency on CAR for cell entry is a fundamental determinant of viral tropism. Furthermore, like some CV-B strains, SVDV also interacts with CD55 (decay-accelerating factor) as a co-receptor, which can be blocked by specific monoclonal antibodies [11]. The amino acid residues of the VP1 capsid protein, particularly residue 178, are known to play essential roles in host tropism, cell entry, and viral decoating. Epistatic interactions involving this residue are crucial for the adaptation of the virus to swine hosts, distinguishing its evolutionary trajectory from its human CV-B5 ancestor [7].

At the genomic level, SVDV shares the typical picornavirus organization. The positive-sense RNA genome encodes a single large polyprotein that is cleaved into structural (P1 region: VP1, VP2, VP3, VP4) and non-structural (P2 and P3 regions) proteins. Phylogenetic analysis of the complete polyprotein coding region reveals a minimum pairwise identity of approximately 85% at the nucleotide level and 98% at the amino acid level among different SVDV isolates, even when compared across different geographic lineages (e.g., Italy, Spain, Portugal) [5]. This high degree of amino acid conservation is consistent with the antigenic homogeneity observed among SVDV strains, which simplifies diagnostic serology but does not preclude the emergence of immune escape variants over long periods. Interestingly, despite decades of circulation in endemic regions, SVDV has not been subject to strong positive selective pressures that would confer a clear evolutionary advantage beyond the major recombination event that occurred in the Italian epidemic [5].

A particularly important event in the recent evolution of SVDV was a recombination event within the 2B coding region, which generated a novel recombinant strain that emerged in Italy circa 2008 [5]. This event gave rise to at least 20 distinct recombinant viruses, which initially co-circulated with their parental strains from two sublineages (1 and 2) before becoming the dominant circulating form until eradication in 2015. This recombination underscores the dynamic nature of RNA virus genomes and demonstrates that despite a high degree of antigenic stability, significant genetic changes can occur through recombination, potentially altering viral fitness, pathogenicity, or tissue tropism. Furthermore, the non-structural protein 2C of SVDV has been implicated in resistance to Golgi-disrupting drugs, with a single Q65H amino acid substitution conferring increased resistance to brefeldin A [10]. This highlights specific protein functions that can be targeted for antiviral research, although no commercially licensed SVDV vaccine exists in most Western countries.

Status and Surveillance

For decades, SVDV was considered endemic in Italy, with major epizootics occurring until eradication was officially declared in 2015 [5, 13]. The Italian experience, particularly the 2006-2007 epidemic in Lombardy, provided critical data on spatial transmission dynamics. Mathematical modeling of this epidemic revealed two distinct phases: an initial phase where transmission over longer distances occurred (likely facilitated by animal movements), followed by a second phase where intensive short-distance transmission became dominant in high-density pig farming areas [13]. This analysis demonstrated that movement restrictions were effective but also highlighted the need for pre-emptive culling in areas with farm densities exceeding a critical threshold for between-farm transmission [13]. The virus has also been reported in other European countries, including Spain and Portugal, where isolates such as the Spanish SPA/1/'93 strain have been fully sequenced [5, 8]. The global risk of introduction into previously free regions, such as Kenya via imported natural sausage casings from Italy, has been quantitatively assessed to be extremely low (probability of (1.9 \times 10^{-8})), given robust surveillance programs in exporting countries [4].

The taxonomy and overview of SVDV are thus inextricably linked to its epidemiology and evolutionary history. It is a virus that, despite being highly contagious and clinically significant, exhibits remarkable genetic stability in its structural proteins but remains vulnerable to major genetic shifts through recombination. The continued circulation of CV-B5 in the human population provides a potential reservoir for future spillover events, meaning that virological surveillance should not be limited to swine but must also consider the human-animal interface. The diagnostic and biosecurity challenges posed by SVDV, including its relative resistance to inactivation compared to enveloped viruses like classical swine fever virus (CSFV), have driven research into effective disinfection protocols. For example, accelerated hydrogen peroxide-based disinfectants and binary ethylenimine (BEI) treatments have been validated for inactivation of SVDV on surfaces and in laboratory settings, respectively [2, 6]. Quaternary ammonium compounds combined with 0.1% sodium hydroxide have also proven highly effective, particularly at elevated temperatures [14]. These measures are essential for maintaining containment and preventing re-emergence in areas that have achieved SVD-free status.

Molecular Pathogenesis of Swine Vesicular Disease Virus

Taxonomic and Evolutionary Context: The Anthroponotic Origin of a Porcine Pathogen

Swine vesicular disease virus (SVDV) is a non-enveloped, single-stranded positive-sense RNA virus belonging to the species Enterovirus B within the family Picornaviridae [8, 10]. Its molecular pathogenesis is inextricably linked to its remarkable evolutionary history: SVDV is not a virus that evolved within swine over millennia, but rather a recent, anthroponotic derivative of the human pathogen coxsackievirus B5 (CV-B5) [9]. Phylogenetic and phylodynamic analyses of the VP1 and partial 3Dpol gene regions have unequivocally demonstrated that SVDV emerged from a single host-switching event from humans to pigs, with the major hubs of CV-B5 transmission located in China and those of SVDV transmission centered in Italy [7]. This singular origin explains the profound genetic and antigenic homology between SVDV and CV-B5, a relationship that is fundamental to understanding the virus’s cellular tropism, receptor usage, and pathogenic mechanisms in the porcine host [9, 11]. The molecular clock dating of this event places the emergence of SVDV in the mid-20th century, a remarkably short evolutionary timeframe for a virus to adapt to a new host species and establish endemicity, particularly in Italy, where it persisted until eradication in 2015 [5, 9].

Receptor-Mediated Entry and Cellular Tropism: The CAR-CD55 Axis

The molecular pathogenesis of SVDV begins at the cell surface, where the virus exploits a receptor complex shared with its human progenitor. The primary receptor for SVDV is the coxsackievirus and adenovirus receptor (CAR), a transmembrane protein of the immunoglobulin superfamily that is highly conserved across mammalian species [11]. Seminal studies using Chinese hamster ovary (CHO) cells transfected with human CAR demonstrated that expression of this receptor alone confers susceptibility to SVDV infection, resulting in a 1,000-fold increase in progeny virus production and the development of characteristic cytopathic effects (CPE) [11]. Critically, infection of these permissive cells could be specifically and completely blocked by a monoclonal antibody directed against CAR (RmcB), confirming that CAR is an essential, functional receptor for SVDV entry [11].

However, the molecular pathogenesis of SVDV is not solely dependent on CAR. The virus, like many group B coxsackieviruses, also engages CD55 (decay-accelerating factor) as a co-receptor or attachment factor [11]. This dual-receptor usage has significant implications for tissue tropism and disease severity. CD55 is a glycosylphosphatidylinositol (GPI)-anchored complement regulatory protein widely expressed on epithelial and endothelial cells, including those of the porcine oral mucosa, coronary band, and skin, the primary sites of vesicular lesion formation. The interaction with CD55 may facilitate initial viral attachment and concentration on the cell surface, followed by high-affinity binding to CAR for internalization. This two-step mechanism is a hallmark of enteroviral pathogenesis and explains the exquisite tropism of SVDV for epithelial tissues, where both CAR and CD55 are co-expressed. The ability of soluble CAR to effectively block SVDV infection of HeLa cell monolayers further underscores the dominance of this receptor pathway in the infectious process [11].

Genomic Organization, Replication, and the Role of Non-Structural Proteins in Pathogenesis

The SVDV genome is approximately 7.4 kb in length, encoding a single polyprotein that is co- and post-translationally cleaved by viral proteases into structural (VP1-VP4) and non-structural (2A-2C, 3A-3D) proteins [8]. The molecular pathogenesis of SVDV is driven by the intricate interplay of these proteins with host cell machinery, particularly the secretory pathway and the Golgi apparatus.

The non-structural protein 2C has emerged as a critical determinant of viral replication and a target for antiviral intervention. SVDV 2C is a multifunctional protein involved in RNA replication, membrane rearrangement, and the formation of replication complexes. A landmark study investigating the effects of Golgi-disrupting drugs on SVDV replication revealed that both brefeldin A (BFA) and golgicide A (GCA) potently inhibit virus production [10]. BFA inhibits guanine nucleotide exchange factors of Arf proteins, leading to the disassembly of the Golgi complex and disruption of the cellular secretory pathway. By selecting for BFA-resistant SVDV mutants, researchers identified a single amino acid substitution, Q65H, in the 2C protein that conferred increased resistance to both BFA and GCA [10]. This finding provides direct molecular evidence that SVDV 2C functionally interacts with components of the Golgi and the Arf-dependent secretory pathway to establish its replication complexes. The Q65H mutation likely alters the conformation of 2C, allowing the virus to replicate more efficiently even when the Golgi architecture is compromised. This highlights a key pathogenic strategy: SVDV hijacks and remodels intracellular membranes, particularly those of the Golgi, to create protected microenvironments for RNA replication, shielding the viral genome from cytoplasmic innate immune sensors.

Recombination as a Major Evolutionary Driver and Its Impact on Pathogenesis

The molecular evolution of SVDV in its endemic Italian niche has been profoundly shaped by recombination. Whole-genome sequencing of 152 viral strains circulating in Italy from 1992 to 2015 revealed a minimum pairwise nucleotide identity of 85% and amino acid identity of 98%, indicating remarkable antigenic homogeneity despite decades of circulation [5]. However, this genetic stability was punctuated by a single, pivotal recombination event. Recombination analysis identified a breakpoint site within the 2B coding region, resulting in a chimeric virus originating from the two co-circulating sublineages (sublineage 1, endemic to Italy since 1995, and sublineage 2, which included strains from Spain and Portugal) [5]. This recombination event, dated to the beginning of 2008, gave rise to at least 20 recombinant strains that initially co-circulated with their parental strains until 2010, after which they became the dominant circulating viruses until eradication in 2015 [5].

The molecular pathogenesis of these recombinant strains is of particular interest. The 2B protein of enteroviruses is a viroporin that modifies membrane permeability and is implicated in the release of viral progeny and the induction of CPE. Recombination in this region could alter the kinetics of viral egress, the extent of host cell lysis, or the ability to counteract host restriction factors. Importantly, the study found that apart from this single recombination event, SVDV was not subject to positive selective pressures that would confer a clear evolutionary advantage [5]. This suggests that the recombination event itself, rather than adaptive point mutations, was the primary driver of the virus’s long-term fitness and persistence. The emergence and dominance of the recombinant strain underscore the capacity of RNA viruses to generate genetic diversity through recombination, a mechanism that can rapidly alter pathogenic potential without the need for gradual mutational accumulation.

Molecular Determinants of Host Switching and Neuropathogenesis

The anthroponotic origin of SVDV implies that specific molecular changes in the viral capsid were necessary to permit efficient infection and transmission in swine. Comparative sequence analyses of the VP1 capsid protein between CV-B5 and SVDV have identified key residues that govern host tropism. Residue 178 of VP1, located on the viral surface near the receptor-binding canyon, has been shown to exhibit four epistatic interactions with residues known to play essential roles in viral host tropism, cell entry, and viral uncoating [7]. These interactions likely modulate the affinity of the virus for porcine CAR and CD55, or alter the pH stability of the capsid required for genome release in the endosome. The network analysis of deduced amino acid sequences revealed a diverse extension of the VP1 structural protein in SVDV compared to CV-B5, suggesting that structural plasticity in this region was critical for adapting to the porcine host [7].

Beyond the characteristic vesicular lesions of the skin and oral mucosa, SVDV exhibits a notable neurotropic potential that is a hallmark of its molecular pathogenesis. Experimental inoculation of pigs with the Hong Kong strain of SVDV resulted in the development of diffuse encephalomyelitis [20]. Histopathological examination revealed perivascular cuffing with lymphocytes and the formation of neuroglia cell foci, with lesions most severe in the diencephalon, mesencephalon, metencephalon, and myelencephalon [20]. This neuropathogenesis is consistent with the known propensity of enterovirus B species, including CV-B5, to cause aseptic meningitis and encephalitis in humans. The ability of SVDV to invade the central nervous system (CNS) likely depends on its capacity to cross the blood-brain barrier, possibly through infection of endothelial cells or via a "Trojan horse" mechanism within infected leukocytes. The neurotropism of SVDV, while often subclinical in natural infections, represents a significant pathogenic dimension that may contribute to the overall disease burden and the establishment of persistent infections in the CNS.

Host Immune Response and Viral Evasion Strategies

The molecular pathogenesis of SVDV is also defined by the dynamic interplay between viral replication and the host immune response. The virus elicits a robust humoral response, with SVDV-specific IgM detectable in oral fluids as early as 6 days post-infection (DPI), peaking at 7-14 DPI, and declining sharply by 21 DPI [16]. In contrast, the IgA response begins at 7 DPI, peaks at 14 DPI, and remains elevated, suggesting a role for mucosal immunity in controlling infection at epithelial surfaces [16]. The detection of viral genome in oral fluids from 1 to 21 DPI, and successful virus isolation from 1-5 DPI, indicates that the virus replicates extensively in the oropharyngeal mucosa, a site that is both a portal of entry and a major site of shedding [16].

The virus has evolved mechanisms to evade or subvert the host immune response. The antigenic homogeneity observed among Italian SVDV strains over two decades (98% amino acid identity in the polyprotein) suggests that the virus is under strong purifying selection to maintain its capsid structure, likely to preserve receptor-binding function and stability [5]. This lack of antigenic drift is a double-edged sword: it facilitates the development of effective vaccines and diagnostic assays (such as virus-like particle-based ELISAs) [17-19], but it also implies that the virus relies on other strategies, such as rapid replication and direct cell-to-cell spread, to outpace the adaptive immune response. The ability of SVDV to cause subclinical infections, particularly in older animals, is a critical aspect of its pathogenesis, allowing the virus to circulate undetected within herds and complicating eradication efforts [3, 15]. The World Organisation for Animal Health (WOAH) recognizes SVD as a notifiable disease precisely because of its clinical similarity to foot-and-mouth disease (FMD) and its potential for silent spread, underscoring the economic and trade implications of its molecular pathogenesis [1, 4, 17].

Epidemiology and Global Distribution of Swine Vesicular Disease Virus

Swine vesicular disease virus (SVDV), a member of the species Enterovirus B within the family Picornaviridae, is an economically significant pathogen of domestic pigs and wild boar that causes a highly contagious vesicular syndrome clinically indistinguishable from foot-and-mouth disease (FMD) [1, 21]. Despite its restricted host range, only suids are naturally infected, SVDV has historically imposed severe trade restrictions on affected regions because of its similarity to FMD, a disease for which the World Organisation for Animal Health (WOAH) maintains zero-tolerance policies for member countries. Understanding the epidemiology and global distribution of SVDV is therefore essential for designing surveillance systems, assessing introduction risks, and implementing effective control measures. This section provides a comprehensive analysis of the virus’s geographic occurrence, phylogenetic diversification, transmission dynamics, and the factors that have shaped its persistence and eventual eradication from several regions.

Historical Emergence and Anthroponotic Origin

Unlike many veterinary pathogens that originate in wildlife, SVDV has a singular and well-documented origin in humans. Molecular and phylodynamic analyses have unequivocally demonstrated that SVDV is a porcine-adapted variant of human coxsackievirus B5 (CV-B5) [7, 9]. The emergence of SVDV is estimated to have occurred in the mid-20th century, with the most recent common ancestor of all known SVDV isolates dating to approximately 1947–1959 [7, 9]. This anthroponotic spillover event likely took place in a setting where pigs were exposed to human sewage or infected human populations, leading to a host-switch that ultimately established a self-sustaining transmission cycle in suids. The coxsackievirus-adenovirus receptor (CAR), which serves as a functional receptor for CV-B5, is also utilized by SVDV, and the virus can additionally interact with CD55 (decay-accelerating factor), providing a molecular basis for its ability to infect porcine cells [11]. The close antigenic and genetic relationship between SVDV and CV-B5 means that human enterovirus surveillance data can occasionally inform veterinary risk assessments, although the two viruses now circulate in distinct hosts.

Global Distribution and Endemicity Patterns

SVDV has never achieved a truly worldwide distribution. Its known geographic range has been largely confined to Europe and parts of Asia, with occasional incursions into Africa via contaminated products. The first recognized outbreaks occurred in Hong Kong in 1971 [20], and the virus subsequently spread to European pig populations. Italy emerged as the primary global reservoir, where SVDV was considered endemic from the early 1990s until 2015 [5]. During this period, Italy experienced approximately 685 reported outbreaks, with the highest concentration in the northern region of Lombardy, a densely populated pig-farming area [5, 13]. Spain and Portugal also experienced significant circulation, with documented outbreaks in 1993 and 2003 [5, 8]. Other European countries, such as the Netherlands, Belgium, France, and Germany, have experienced sporadic outbreaks linked to live pig movements or contaminated meat products, but these were typically contained through stamping-out policies.

Outside Europe, SVDV has been reported in Japan and Taiwan, and there is serological evidence of past circulation in the People’s Republic of China [7]. The virus has never been reported in Kenya or elsewhere in sub-Saharan Africa, but a quantitative risk assessment demonstrated a non-zero probability of introduction via natural sausage casings imported from Italy, estimated at (1.9 \times 10^{-8}) per consignment [4]. This low but finite risk underscores the importance of rigorous surveillance in exporting countries and the need for WOAH-compliant import protocols, especially for porcine-derived products.

Phylogenetic Lineages and Evolutionary Dynamics

Based on analyses of the VP1 gene, SVDV isolates can be classified into three major genotypes (I–III) [7]. Genotype I contains the oldest known isolates and is associated with early outbreaks in Hong Kong and southern Europe. Genotype II emerged later and predominated in the Italian epidemics from the 1990s onward. Genotype III is more heterogeneous and includes strains from the Iberian Peninsula. Whole-genome sequencing of Italian strains collected between 1992 and 2015 has further resolved two sublineages within the Italian epidemic: sublineage 1, which evolved and circulated exclusively within Italy after 1995, and sublineage 2, which also includes strains from Spain (1993) and Portugal (2003) [5]. This clustering reflects both independent viral evolution in geographically separated pig populations and occasional cross-border transmission facilitated by animal trade.

A landmark finding from the Italian eradication campaign was the detection of a recombination event within the 2B coding region, giving rise to a novel recombinant strain dated to early 2008 [5]. This recombinant, which arose from co-infection of parental viruses belonging to the two sublineages, generated at least 20 progeny that co-circulated with their progenitors until around 2010 and then persisted alone until eradication in 2015. Notably, apart from this single recombination event, SVDV showed no evidence of positive selective pressure over its >20-year presence in Italy, suggesting that the virus was not undergoing rapid antigenic drift [5]. This relative genetic stability explains the success of diagnostic tools and vaccines based on early reference strains.

Transmission Dynamics and Spatial Epidemiology

SVDV is highly contagious and spreads primarily through direct contact between pigs, via the fecal-oral route, and indirectly through contaminated fomites, feed, water, and vehicles [1, 3]. The virus is remarkably stable in the environment; it can survive for weeks on contaminated surfaces and for extended periods in meat products, which is why international trade in pork and casings represents a risk pathway [4, 21]. Experimental infections have shown that pigs can shed virus in feces for up to 21 days and in oral fluids from 1 day post-infection, providing a window for rapid spread within holdings [16]. Subclinical infections, which are common in older animals and in herds with partial immunity, complicate detection and allow the virus to circulate undetected [3, 15].

The spatial transmission of SVDV was rigorously analyzed during the 2006–2007 epidemic in Lombardy, Italy [13]. This epidemic comprised two distinct sub-epidemics. In the first, transmission over relatively long distances was higher, reflecting the movement of infected pigs before restrictions were imposed. After movement controls were implemented, the second sub-epidemic showed a marked shift to short-distance transmission, with a higher probability of between-farm spread occurring within a radius of a few kilometers. Model fitting revealed that the local farm density in the affected area exceeded a critical threshold, explaining the persistent localized transmission. This finding provided the scientific basis for pre-emptive culling in high-density areas, a measure that contributed to eventual eradication [13].

The fecal-oral route is the dominant transmission mechanism under standard husbandry conditions. In an experimental setting, intradermally infected pigs housed under strict biosecurity did not transmit infection to co-housed sentinels, indicating that close contact or contaminated fomites are required [3]. However, under commercial conditions, shared equipment, personnel movement, and inadequate cleaning facilitate rapid dissemination.

Diagnostic Surveillance and Eradication Programs

Because SVDV is clinically indistinguishable from FMD, vesicular stomatitis, and Senecavirus A infection, laboratory confirmation is mandatory for any suspect case [1, 17]. The OIE (now WOAH) requires that all vesicular conditions be investigated immediately. For decades, Italy maintained an intensive surveillance program based on serological testing using competitive ELISA and virus neutralization, complemented by RT-PCR detection of viral RNA in fecal samples [15, 17]. A 2020 study comparing six genomic amplification assays demonstrated that conventional RT-PCR and SYBR Green-based real-time assays targeting the 3D polymerase gene achieved the highest diagnostic sensitivity, detecting all SVDV lineages circulating in Italy from 1997 to 2014 [15]. In contrast, a TaqMan assay showed reduced sensitivity due to mismatches in the probe target, and reverse-transcriptase loop-mediated isothermal amplification (RT-LAMP) assays targeting the 5′UTR failed to detect isolates from one sub-lineage [15]. These findings emphasize the necessity of selecting broad-spectrum molecular targets for long-term surveillance.

Serological monitoring has also advanced through the development of recombinant virus-like particle (VLP)-based ELISAs. The VLP platform, which avoids the need for live virus, provides high specificity (99.9%) and sensitivity comparable to the gold standard virus neutralization test [18, 19]. Isotype-specific ELISAs for IgM and IgG have further reduced false-positive rates, thereby minimizing trade disruptions [17]. The availability of non-infectious antigens has been instrumental in allowing safe, high-throughput testing in national reference laboratories.

Current Status: Eradication and Residual Risks

Italy officially declared SVD eradicated in 2015, following a sustained control program that combined movement restrictions, pre-emptive culling, enhanced biosecurity, and intensive diagnostic surveillance [5, 15]. No further outbreaks have been reported in the country. Spain and Portugal have also been free of SVDV for decades, and the rest of the European Union is considered free. Nevertheless, the virus remains a latent threat because of its environmental stability and the persistence of susceptible wild boar populations in some regions. Furthermore, the recent emergence of Senecavirus A, which produces a similar clinical picture, complicates field diagnosis in areas where SVDV has been eradicated, requiring continued vigilance [6].

The risk of re-introduction into SVD-free regions exists through several routes: illegal movement of infected pigs, contaminated pork products shipped internationally, and inadvertent transfer via fomites or vehicles returning from endemic areas. The quantitative risk assessment for Kenya, which imports natural sausage casings from Italy, estimated a very low probability of introduction ((1.9 \times 10^{-8})) based on Italian surveillance data and current mitigations [4]. However, if surveillance in exporting countries were to lapse, or if casings originated from unreported outbreaks, the risk could increase by several orders of magnitude.

Implications for Global Biosecurity and Trade

SVDV remains listed by WOAH as a notifiable disease, despite its narrow host range and low mortality. The economic consequences of an outbreak in a previously free region are severe, primarily due to the immediate suspension of international pig and pork trade. The European Union and other trading blocs require that any SVDV outbreak be controlled by stamping out, which can lead to the destruction of thousands of animals and compensation costs in the millions of euros. The experience of Italy demonstrates that eradication is feasible but requires sustained political will, substantial financial investment, and a robust laboratory network capable of rapid and accurate diagnosis [5, 15].

In conclusion, the global distribution of SVDV has contracted dramatically since its peak in the 1990s, with Italy being the last major endemic focus. The virus’s evolution has been characterized by genetic stability and a single recombination event, and its transmission is driven by fecal-oral shedding and farm density. International surveillance, combined with modern molecular diagnostics and safe serological assays, ensures that any resurgence can be detected early. The eradication of SVDV from Italy serves as a model for the control of other vesicular diseases, but it also highlights the importance of maintaining surveillance even after freedom from disease is declared.

Clinical Presentation and Differential Diagnosis of Swine Vesicular Disease

Swine vesicular disease (SVD) is a contagious viral illness of pigs that, in its acute form, produces a clinical syndrome virtually indistinguishable from foot-and-mouth disease (FMD), a fact that has profound implications for international trade and veterinary public health [3, 17, 18]. The disease, caused by swine vesicular disease virus (SVDV), an enterovirus within the Picornaviridae family that is genetically and antigenically allied to human coxsackievirus B5 [7, 9, 12], presents a spectrum of clinical manifestations that range from severe, debilitating vesicular disease to entirely subclinical infections. This variability, coupled with the existence of multiple other vesicular and non-vesicular conditions that can mimic SVD, renders a deep understanding of its clinical presentation and a rigorous approach to differential diagnosis absolutely essential for swine practitioners and diagnostic laboratories, particularly in regions that are free of FMD and maintain high health status for their swine herds.

Clinical Presentation: A Spectrum of Vesicular Disease

The clinical picture of SVD is defined by the formation of vesicles, fluid-filled blisters, on the coronary bands of the feet, the interdigital spaces, the snout, the tongue, and less commonly, the teats of sows [3]. The incubation period following exposure is typically 2 to 7 days, though it can be longer depending on the route of infection and the viral dose [3, 16]. Experimental infection of pigs with the SVDV strain 2348 Italy/2008, delivered intradermally at a high dose of 10⁹ TCID₅₀, produced the classic signs of acute disease, confirming the virulent potential of contemporary strains [3].

The initial clinical signs are often subtle and non-specific. Affected pigs may exhibit a transient pyrexia (fever), lethargy, and a reduction in feed intake. Within 24 to 48 hours, the characteristic vesicles begin to appear. These lesions typically start as pale, raised areas of epidermis that rapidly progress to fluid-filled vesicles, ranging from a few millimeters to several centimeters in diameter. The vesicular fluid is initially clear but may become serosanguinous as the lesion matures [25]. The most consistent and pathognomonic finding is lameness. Pigs will be reluctant to stand or walk, and when forced to move, they exhibit a characteristic shifting of weight from one foot to another, often attempting to walk on their knees. The severity of lameness is directly correlated with the location and size of the foot lesions. Lesions on the coronary band can cause the hoof wall to partially separate, a condition known as "thimble" or "slipper" foot, which is profoundly painful.

Within 24 to 72 hours of their appearance, the vesicles rupture, leaving raw, hemorrhagic erosions and ulcers. These secondary lesions are highly susceptible to bacterial contamination, leading to purulent exudate, crusting, and in severe cases, secondary septicemia. While the oral and snout lesions heal relatively quickly, often within a week, the foot lesions can be more protracted, sometimes taking 2 to 3 weeks to fully re-epithelialize, particularly if complicated by secondary infection. The healing process often leaves visible scars on the coronary band, which are permanent markers of previous infection. It is crucial to note that while morbidity in an affected herd can approach 100%, mortality is exceptionally low, a key differentiating feature from highly lethal diseases like African swine fever (ASF) [1, 12, 21]. However, the economic impact is severe due to weight loss, reduced growth rates, condemnation of meat at slaughter, and the trade restrictions that follow an outbreak.

A critical feature of SVDV infection, and one that makes its control and eradication immensely challenging, is the high prevalence of subclinical or inapparent infections. Indeed, for more than two decades in Italy, SVD occurred predominantly in a subclinical form, with the virus circulating undetected in pig populations [15]. This subclinical state is now considered a hallmark of the disease in endemic settings. Infected pigs show no overt clinical signs but can shed large quantities of virus in their feces for extended periods, serving as silent reservoirs that perpetuate the infection cycle [15, 16]. The detection of this silent circulation has relied heavily on active surveillance, including the testing of fecal samples from both suspect holdings and high-turnover premises, and more recently, the use of oral fluids [15, 16]. Research has demonstrated that SVDV genome can be detected in oral fluids as early as 1 day post-infection and for up to 21 days, making this a highly sensitive, non-invasive tool for identifying subclinical carriers [16]. This ability to maintain a prolonged, asymptomatic carrier state is a critical evolutionary adaptation of SVDV and a primary reason why stamping-out policies, while effective, are so disruptive.

Beyond the classic vesicular syndrome, SVDV infection can also manifest with neurological involvement. Early experimental studies using the Hong Kong strain of SVDV demonstrated that intravenously inoculated pigs developed a diffuse, non-suppurative encephalomyelitis [20]. Histopathological lesions, characterized by perivascular cuffing with lymphocytes and the formation of glial cell foci, were most severe in the diencephalon, mesencephalon, metencephalon, and myelencephalon [20]. While these neurological signs are not the most common presentation, they underscore the pantropic nature of the virus and its ability to invade the central nervous system, potentially contributing to non-specific signs such as ataxia, muscle tremors, or convulsive episodes in some infected animals. This is an important consideration when differentiating SVD from other neurological diseases of swine.

Differential Diagnosis: The Critical Imperative

The single most important clinical challenge posed by SVD is its absolute clinical indistinguishability from FMD [1, 3, 17, 18]. Both diseases present with identical vesicular lesions on the snout, tongue, and feet, accompanied by fever, lameness, and drooling. The World Organisation for Animal Health (WOAH) mandates that any outbreak of vesicular disease in pigs must be treated as a potential FMD case until laboratory testing proves otherwise. This is not merely a clinical nicety; it is a fundamental principle of veterinary biosecurity and international trade law. The misdiagnosis of FMD as SVD, or vice versa, would have catastrophic economic consequences. Therefore, vesicular stomatitis virus (VSV), a disease of cattle, horses, and pigs, must also be included in the differential list, as it can produce identical lesions in swine [6, 22]. While VSV is endemic in parts of the Americas, it is exotic to Europe and many other regions, making it a critical consideration in imported animals or when a vesicular disease occurs in a previously free area.

The differential diagnosis for SVD is not limited to the classic vesicular diseases. Senecavirus A (SVA), a recently emerged picornavirus, has been shown to cause a clinically identical syndrome in pigs, known as porcine idiopathic vesicular disease (PIVD) [6, 17]. The emergence of SVA has added a new layer of complexity to the differential workup, as it can now mimic both FMD and SVD. Laboratory differentiation via real-time reverse transcription polymerase chain reaction (RRT-PCR) is the only reliable method to distinguish these three viruses. Furthermore, non-viral conditions can produce lesions that mimic SVD. Chemical burns (from caustic agents like lime or strong disinfectants), sunburn, and photosensitization can all cause vesiculation, erythema, and sloughing of the skin, particularly on the snout and dorsum. Contact dermatitis from wet bedding or poor hygiene can also cause interdigital lesions. Photodynamic dermatitis, caused by ingestion of certain plants or drugs, can produce severe lesions that may be confused with vesicular diseases. Finally, trauma from abrasive flooring, especially in newly housed pigs, can lead to coronary band and foot pad erosions that look remarkably like early vesicular lesions.

Other systemic diseases must also be considered. African swine fever (ASF) and classical swine fever (CSF) can both cause skin hemorrhages, cyanosis, and secondary lesions, but they are typically accompanied by high fever, profound depression, and significant mortality, features that are not characteristic of SVD [21, 23]. However, in a herd where ASF is circulating, a pig with traumatic foot lesions could easily trigger an erroneous FMD/SVD investigation. The diagnostic algorithm, therefore, must be exhaustive. A thorough history is paramount: recent introductions, feed source, exposure to chemicals, and vaccination status against swine diseases are all critical pieces of information. A complete physical examination, with careful palpation of all four feet, the mouth, and the snout, is mandatory. Lesion distribution can offer clues: SVDV and FMDV lesions are most commonly found on the feet, while VSV lesions are often more prominent on the snout and oral mucosa, but this is not a reliable rule. The presence of systemic illness (fever, depression, high mortality) strongly points away from SVD and toward ASF or CSF.

Given the clinical impossibility of a definitive diagnosis at the farm level, the immediate action when a vesicular disease is suspected is to contact the state or federal veterinary authority, impose a quarantine on the affected premises, and collect appropriate diagnostic samples. The recommended samples, per WOAH guidelines, include vesicular fluid, epithelial tissue from the roof of an unruptured or recently ruptured vesicle, and blood (for serology). For the detection of subclinical infections, fecal samples or oral fluids are the specimens of choice, with RRT-PCR being the most sensitive and widely used detection method [15, 16]. Virus isolation in cell culture (e.g., IB-RS-2 cells) can be attempted, but it is less rapid and requires high-containment facilities [2, 24]. Serological tests, such as the virus neutralization test (VNT), competitive ELISA (cELISA), and isotype-specific ELISAs, are used to confirm prior exposure or to differentiate vaccinated from infected animals [16, 17, 19]. The development of recombinant virus-like particle (VLP)-based ELISAs has provided a safer, non-infectious alternative to inactivated whole-virus antigens for serological diagnosis, reducing the risk of accidental release of live virus [17-19]. The diagnostic approach, therefore, must be a coordinated, multi-step process that begins with a high index of clinical suspicion and ends with definitive laboratory confirmation, a process that is the bedrock of global vesicular disease control.

Diagnostic Methods for Swine Vesicular Disease Virus Detection

The accurate and timely detection of swine vesicular disease virus (SVDV) is a cornerstone of effective disease surveillance, outbreak containment, and international trade certification. The diagnostic landscape for SVDV is complex, driven by the virus's clinical indistinguishability from other vesicular diseases, most notably foot-and-mouth disease (FMD), Senecavirus A (SVA), and vesicular stomatitis, and its capacity for subclinical circulation, particularly in endemic or recently eradicated regions. The World Organisation for Animal Health (WOAH) mandates that any vesicular condition in swine must be investigated as a foreign animal disease emergency, underscoring the need for a multi-tiered diagnostic arsenal that combines rapid screening with definitive confirmatory methods. This section provides an exhaustive analysis of the current virological, molecular, serological, and advanced diagnostic modalities available for SVDV detection, contextualized by the biological properties of the virus and the epidemiological realities of its transmission.

Virological Methods: Virus Isolation and Cell Culture

Virus isolation remains a gold standard for definitive SVDV diagnosis, providing live virus for downstream characterization, phylogenetic analysis, and antigenic mapping. SVDV, an enterovirus within the Picornaviridae family, exhibits a pronounced tropism for porcine-derived cell lines. The most sensitive and widely utilized cell lines include IB-RS-2 (a swine kidney cell line), SK-6, and PK-15 cells [3, 24]. Experimental adaptation of field strains, such as the Italian isolate 2348 Italy/2008, to IB-RS-2 monolayers has confirmed that these cells support robust viral replication, yielding titers sufficient for subsequent diagnostic applications, including virus neutralization tests (VNT) and antigen production [3]. The replication kinetics of SVDV in these cell systems can be precisely monitored using real-time impedance measurement technologies, such as the xCELLigence system, which quantifies cytopathic effect (CPE) as a reduction in cell index (CI). This approach allows for dynamic, non-invasive assessment of viral replication, with studies demonstrating that IB-RS-2 cells exhibit the highest sensitivity to SVDV infection, followed by SK-6, when compared to traditional end-point CPE observation [24]. In practice, clinical specimens, typically vesicular fluid, epithelial tissue swabs, or fecal samples, are inoculated onto confluent cell monolayers, and CPE is assessed over 48–72 hours. Positive cultures are then confirmed by immunofluorescence or RT-PCR. While virus isolation provides unequivocal evidence of infectious virus, it is labor-intensive, requires high-containment biosafety level 3 (BSL-3) facilities, and may take several days, delaying critical control decisions. Furthermore, the viability of SVDV in clinical samples can be compromised by improper handling or storage, as the virus is known to be relatively thermostable but susceptible to inactivation by heat treatment (70°C for 24–48 hours) and chemical disinfectants such as binary ethylenimine (BEI) [2, 21]. These logistical constraints have driven the adoption of molecular methods as primary screening tools.

Molecular Diagnostic Methods: RT-PCR, Real-Time RT-PCR, and RT-LAMP

Nucleic acid amplification techniques have revolutionized SVDV detection, offering unparalleled sensitivity, specificity, and speed. Given that SVDV possesses a positive-sense single-stranded RNA genome approximately 7.4 kb in length, reverse transcription followed by polymerase chain reaction (RT-PCR) is the foundational approach. A comprehensive evaluation of six genomic amplification assays using 78 positive fecal samples from Italian outbreaks spanning 1997–2014 provides critical insights into assay performance relative to viral genetic diversity [15]. The study compared three RT-PCR assays targeting a 154-nucleotide fragment of the conserved 3D polymerase gene: a conventional RT-PCR, a SYBR Green-based real-time RT-PCR, and a TaqMan probe-based real-time RT-PCR. The conventional and SYBR Green assays demonstrated 100% diagnostic sensitivity across all tested lineages, while the TaqMan assay failed to detect three samples due to two nucleotide mismatches in the probe-binding region, highlighting the risk of probe-based assays when targeting genetically variable viruses [15]. Additionally, a reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assay and two 5′ untranslated region (UTR)-targeted real-time RT-PCRs were evaluated. The 5′UTR assays exhibited reduced performance, failing to detect viruses from a specific sub-lineage due to multiple primer and probe mismatches, underscoring the critical importance of assay design informed by ongoing phylogenetic surveillance [15].

For simultaneous screening of multiple vesicular disease pathogens, multiplex PCR strategies have been developed. A double PCR method capable of concurrently detecting African swine fever virus (ASFV) and SVDV was optimized with specific primers targeting the ASFV P72 protein gene and the SVDV genome, achieving a detection limit of 7.6 × 10² copies/μL for SVDV and demonstrating high specificity with no cross-reactivity to porcine circovirus, pseudorabies virus, or porcine parvovirus [23]. This approach is particularly valuable for differential diagnosis in regions where both diseases are endemic or suspected. The diagnostic landscape must also contend with the genetic evolution of SVDV, including recombination events. Whole-genome sequencing of Italian strains from 1992 to 2015 revealed a recombination breakpoint within the 2B coding region, giving rise to a recombinant lineage that circulated alongside parental strains [5]. Such events can alter primer and probe binding sites, necessitating periodic revalidation of molecular assays. The use of near-complete genome sequencing using platforms like Roche GS FLX, which employs a single PCR primer set to amplify the entire protein-coding region, provides a robust method for monitoring viral evolution and ensuring diagnostic assays remain fit for purpose [12]. For rapid field-deployable detection, RT-LAMP offers advantages in resource-limited settings, as it operates at a constant temperature and does not require thermocyclers; however, its sensitivity is heavily dependent on primer design and may be compromised by the same genetic drift that affects RT-PCR assays [15].

Serological Methods: Virus Neutralization Test, Competitive ELISA, and Isotype-Specific ELISAs

Serological testing is indispensable for surveillance in non-vaccinating countries, confirming past exposure, and certifying animals for international movement. The virus neutralization test (VNT) is the historical gold standard, relying on the ability of serum antibodies to neutralize SVDV infectivity in cell culture. Reference sera, such as those generated from experimental infection of pigs with strain 2348 Italy/2008, are used to calibrate VNT and provide positive controls [3]. However, VNT is labor-intensive, requires live virus and cell culture facilities, and takes 3–5 days to obtain results, making it unsuitable for high-throughput screening.

The primary serological tool for routine surveillance is the competitive enzyme-linked immunosorbent assay (cELISA), which uses monoclonal antibodies (mAbs) targeting the viral structural proteins, most commonly mAb 5B7. While cELISA is highly specific, a recognized limitation is the occurrence of false-positive results, which can disrupt trade and necessitate costly confirmatory testing. To address this, isotype-specific ELISAs based on recombinant virus-like particles (VLPs) have been developed. VLPs are generated by expressing the P1 and 3CD proteins of SVDV in baculovirus systems, resulting in non-infectious particles that morphologically and antigenically resemble native virions [17-19]. The SVD-VLP isotype-ELISAs for IgM and IgG demonstrated diagnostic specificities of 98.7% and 99.6%, respectively, and eliminated cross-reactivity with other vesicular disease viruses [17]. When applied to a panel of 303 sera that were positive by cELISA but from animals with no history of SVDV exposure, the VLP-based isotype-ELISAs correctly identified only five IgM-positive and five IgG-positive samples, suggesting that the vast majority of cELISA positives were false positives [17]. This combined approach, using cELISA for initial screening followed by VLP isotype-ELISAs, significantly reduces the need for VNT confirmation, streamlining diagnostic workflows and expediting trade certification [17, 19]. The serological response in SVDV infection is characterized by an early IgM peak at 7–14 days post-infection, followed by a sustained IgG response. Importantly, antibodies can be detected as early as 3 days post-infection using VLP-based blocking ELISAs, matching the sensitivity of VNT [19]. The detection of IgA in oral fluids through indirect ELISAs offers a non-invasive sampling alternative, with IgA persisting at high levels until at least 21 days post-infection, making it a valuable tool for herd-level surveillance [16].

Advanced and Emerging Diagnostic Technologies

The integration of innovative sampling matrices and sequencing technologies is expanding the frontiers of SVDV diagnostics. The use of swine oral fluids for pathogen detection represents a paradigm shift in surveillance efficiency. In experimentally infected pigs, SVDV genomic RNA was detected in oral fluids by real-time RT-PCR from 1 to 21 days post-infection, with virus isolation successful only during the first 5 days [16]. The presence of SVDV-specific IgM and IgA in oral fluids, detected using adapted ELISAs, provides a robust means of monitoring seroconversion without the need for individual animal handling, which is particularly advantageous for large-scale surveillance in high-turnover facilities [16].

For genomic epidemiology and outbreak tracing, next-generation sequencing (NGS) has become indispensable. A rapid method employing a single PCR amplification of the near-complete SVDV genome, followed by deep sequencing on a Roche GS FLX platform, has been validated for generating high-confidence consensus sequences [12]. This approach enables the reconstruction of transmission networks, identification of recombinant strains, and monitoring of antigenic drift that could impact diagnostic assay performance. The phylogenetic structure of SVDV, comprising three main genotypes (I–III) and two sublineages in Italy, can be resolved through VP1 and 3Dpol sequencing, facilitating spatiotemporal analysis of viral spread [7-9]. Such data are critical for risk assessment frameworks, as demonstrated by quantitative risk models evaluating the introduction of SVDV into Kenya via imported natural sausage casings from Italy, which highlighted the role of rigorous surveillance in mitigating risk [4].

Finally, the development of non-infectious antigen alternatives, such as VLPs, addresses biosafety concerns associated with handling live SVDV for diagnostic antigen production. The recombinant SVD-VLP antigen, produced in baculovirus expression systems, not only replaces inactivated whole virus in ELISAs but also serves as a safe substrate for functional studies, including receptor interaction analysis, given that SVDV utilizes the coxsackie-adenovirus receptor (CAR) for cell entry [11, 18, 19]. This synthetic biology approach enhances the sustainability and safety of diagnostic reagent supply chains, particularly in reference laboratories that must operate under stringent biosecurity protocols.

Inactivation, Biosecurity, and Decontamination Strategies for Swine Vesicular Disease Virus

The development and implementation of robust inactivation, biosecurity, and decontamination protocols are paramount for the control and eradication of Swine Vesicular Disease Virus (SVDV). As a highly resilient member of the Picornaviridae family, specifically classified within the Enterovirus B species and genetically and antigenically akin to human coxsackievirus B5 [7, 9, 12], SVDV presents unique challenges for biosecurity. Its non-enveloped structure confers exceptional stability in the environment, enabling prolonged survival on fomites, in organic matter, and within animal products such as natural sausage casings [4, 21]. This inherent tenacity necessitates a multi-faceted approach to decontamination, combining physical inactivation methods, validated chemical virucides, and stringent biosecurity measures to prevent both introduction and between-farm transmission. The economic consequences of an SVDV outbreak are severe, primarily due to trade restrictions imposed by the World Organisation for Animal Health (WOAH), as the clinical signs are indistinguishable from Foot-and-Mouth Disease (FMD) [1, 3, 17]. Therefore, a deep understanding of the virus’s vulnerabilities is not merely an academic exercise but a critical component of national and international disease control strategies.

Thermal and Physical Inactivation: The Role of Heat Treatment

Given the environmental persistence of SVDV, thermal inactivation represents a cornerstone of decontamination, particularly for facilities and equipment that cannot be subjected to liquid chemical disinfectants. The efficacy of heat treatment is highly dependent on temperature, exposure time, and the matrix in which the virus is embedded. A seminal study by Kristensen et al. (2021) systematically evaluated the heat inactivation of SVDV alongside FMDV and Classical Swine Fever Virus (CSFV) when air-dried on plastic and glass surfaces [21]. This research is directly applicable to decommissioning high-containment laboratories and stables, where fumigation may be impractical due to building material incompatibility. The study demonstrated that SVDV, when air-dried, was inactivated to below the limit of detection after 24 to 48 hours of continuous incubation at 70°C [21]. In stark contrast, the same virus samples retained infectivity for up to seven days when maintained at room temperature, underscoring the critical need for active heating protocols rather than relying on ambient conditions [21].

The mechanism of thermal inactivation involves the denaturation of viral structural proteins, particularly the capsid proteins (VP1-VP4), which are essential for receptor binding and cell entry. SVDV utilizes the coxsackievirus-adenovirus receptor (CAR) and potentially CD55 for cellular attachment [11]. The heat-induced disruption of these protein structures renders the virus incapable of initiating infection, even if the RNA genome remains intact. From a practical standpoint, these findings provide a validated framework for risk assessments and decontamination protocols. For instance, equipment that can withstand prolonged high temperatures, such as metal tools, glassware, and certain plastics, can be effectively decontaminated by placing them in a hot-air oven at 70°C for a minimum of 48 hours. This method offers a non-corrosive, residue-free alternative to chemical disinfection, making it ideal for sensitive laboratory equipment. Furthermore, this data is critical for the WOAH and national veterinary authorities when establishing guidelines for the safe decommissioning of biocontainment facilities, ensuring that residual viral risks are eliminated without compromising structural integrity.

Chemical Inactivation: Validated Virucidal Agents

Chemical disinfection is the most widely employed strategy for routine biosecurity, outbreak response, and laboratory inactivation of SVDV. However, the virus’s robust, non-enveloped nature renders it resistant to many common disinfectants that are effective against enveloped viruses like Influenza A or the virus causing African Swine Fever (ASF). Therefore, specific, validated chemical agents must be used.

Binary Ethylenimine (BEI) for Laboratory and Vaccine Production

In high-containment laboratory settings and for the production of inactivated vaccines, Binary Ethylenimine (BEI) is the gold standard for ensuring complete viral inactivation while preserving antigenic integrity. Wu et al. (2020) conducted a rigorous curve-based validation study to establish a BEI inactivation protocol for SVDV, FMDV, and Vesicular Stomatitis Virus (VSV) [2]. This study is particularly authoritative as it meets the stringent requirements of the United States Federal Select Agent Program (FSAP) for the exclusion of select agents. The research established a linear correlation between virus titer reduction and BEI concentration, treatment time, and temperature. The validated protocol involves two sequential doses of 1.5 mM BEI at 37°C: a first dose for 24 hours, followed by a second dose for an additional 6 hours, totaling 30 hours of contact time [2]. This dual-dose approach ensures complete inactivation of SVDV, confirmed by virus titration and three consecutive blind passages on susceptible cell monolayers (e.g., IB-RS-2 or SK-6 cells) [2, 24]. The mechanism of BEI involves alkylation of the viral RNA, specifically targeting the N7 position of guanine, which prevents replication. This method is indispensable for the safe production of diagnostic antigens, virus-like particles (VLPs), and inactivated whole-virus antigens used in serological assays like the competitive ELISA (cELISA) [17-19].

Accelerated Hydrogen Peroxide (AHP) and Quaternary Ammonium Compounds (QACs)

For field decontamination of surfaces, equipment, and vehicles, accelerated hydrogen peroxide (AHP) and quaternary ammonium compounds (QACs) have demonstrated significant efficacy against SVDV. Hole et al. (2017) evaluated an AHP-based disinfectant against SVDV, FMDV, and Senecavirus A, finding it to be a fast-acting and effective virucide with a favorable safety profile compared to harsh chemicals like chlorine or phenolics [6]. AHP works through the generation of free hydroxyl radicals that attack viral proteins, lipids, and nucleic acids, providing broad-spectrum activity. Its rapid decomposition into water and oxygen makes it environmentally benign, a critical advantage for use in animal housing facilities.

The efficacy of QACs, particularly didecyldimethylammonium chloride (DDAC), is significantly enhanced when combined with an alkaline booster. Shirai et al. (1997) demonstrated that DDAC with 0.1% sodium hydroxide (NaOH) exerts a potent virucidal effect against SVDV, achieving inactivation within one minute of contact at 40°C [14]. The mechanism is synergistic: the 0.1% NaOH partially disrupts the viral capsid, rendering the particles susceptible to aggregation by the DDAC molecules, which then form micelles around the damaged virions, effectively stripping them of infectivity [14]. The study emphasized that the virucidal activity is pH-dependent, being most effective at pH values around 11.0 [14]. This combination is particularly effective against enteroviruses and is recommended for use in footbaths, vehicle dips, and high-pressure sprayers during outbreak control. It is crucial to note that standard QACs without an alkaline component or at neutral pH are largely ineffective against SVDV, highlighting the necessity for using specifically formulated products.

Biosecurity and Risk Mitigation in the Pork Supply Chain

Biosecurity for SVDV extends beyond direct disinfection to encompass the entire production and trade chain, with a particular focus on preventing introduction via contaminated animal products. The virus’s ability to persist in meat and by-products, such as natural sausage casings derived from pig intestines, represents a significant pathway for transboundary spread. A quantitative risk assessment by Dibaba (2019) modeled the probability of introducing SVDV into Kenya via imported natural casings from Italy [4]. The model, using Monte Carlo simulations, estimated the annual probability of introduction to be exceptionally low (1.9 x 10⁻⁸), contingent upon rigorous surveillance programs in the exporting country [4]. This analysis underscores the critical role of pre-export testing and surveillance as a primary biosecurity layer. The study identified that the critical pathway for risk reduction is the implementation of robust surveillance in the country of origin, which can dramatically reduce the number of infected pigs entering the slaughter chain [4].

Furthermore, the epidemiology of SVDV transmission between farms is heavily influenced by movement restrictions and farm density. An analysis of the 2006-2007 epidemic in Lombardy, Italy, by Nassuato et al. (2013) used a spatial transmission model to demonstrate that the implementation of movement restrictions effectively curtailed long-distance spread [13]. However, in high-density pig farming areas, intense local transmission persisted, even with restrictions in place, because the farm density exceeded a critical threshold for local spread [13]. This finding provides a quantitative rationale for pre-emptive culling in high-density zones as an additional control measure. The biosecurity implications are clear: while movement bans are essential, they must be supplemented by enhanced local biosecurity, including rigorous cleaning and disinfection of transport vehicles, strict control of personnel movement, and the use of dedicated farm-specific equipment, to break the chain of local transmission. The use of oral fluids for surveillance, as demonstrated by Senthilkumaran et al. (2017), can serve as a non-invasive, cost-effective tool for early detection of viral circulation within a herd, enabling a rapid biosecurity response before widespread environmental contamination occurs [16].

References

[1] Harris TJ. Swine vesicular disease virus.. Nursing mirror and midwives journal. 2022. DOI: https://doi.org/10.1201/b19719-13

[2] Wu P, Rodríguez YY, Hershey B, Tadassa YF, Dodd K, Jia W. Validation of a binary ethylenimine (BEI) inactivation procedure for biosafety treatment of foot-and-mouth disease viruses (FMDV), vesicular stomatitis viruses (VSV), and swine vesicular disease virus (SVDV).. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108928

[3] Kalinina YN, Fomina SN. Biological properties of swine vesicular disease virus strain 2348 Italy/2008. Veterinary Science Today. 2021. DOI: https://doi.org/10.29326/2304-196x-2021-3-38-203-208

[4] Dibaba AB. The risk of introduction of swine vesicular disease virus into Kenya via natural sausage casings imported from Italy.. Preventive Veterinary Medicine. 2019. DOI: https://doi.org/10.1016/J.PREVETMED.2019.104703

[5] Bregoli A, Benedetti D, Calzolari M, Benevenia R, Nardo AD, Castelli A, et al.. Genetic evolution of swine vesicular disease viruses circulating in Italy from 1992 to the eradication in 2015 and emergence of a recent recombinant strain. Virus Evolution. 2025. DOI: https://doi.org/10.1093/ve/veaf066

[6] Hole K, Ahmadpour F, Krishnan J, Stansfield C, Copps J, Nfon C. Efficacy of accelerated hydrogen peroxide® disinfectant on foot‐and‐mouth disease virus, swine vesicular disease virus and Senecavirus A. Journal of Applied Microbiology. 2017. DOI: https://doi.org/10.1111/jam.13361

[7] Huang H, Chu P, Pan C, Wang C, Lin C, Lu P, et al.. Evolutionary histories of coxsackievirus B5 and swine vesicular disease virus reconstructed by phylodynamic and sequence variation analyses. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-27254-y

[8] Vázquez-Calvo Á, Saiz J, Sobrino F, Martín-Acebes MA. First Complete Coding Sequence of a Spanish Isolate of Swine Vesicular Disease Virus. Genome Announcements. 2016. DOI: https://doi.org/10.1128/genomeA.01742-15

[9] Bruhn CAW, Bruhn CAW, Nielsen SC, Nielsen SC, Samaniego JA, Wadsworth J, et al.. Viral meningitis epidemics and a single, recent, recombinant and anthroponotic origin of swine vesicular disease virus. Evolution, Medicine and Public Health. 2015. DOI: https://doi.org/10.1093/emph/eov026

[10] Vázquez-Calvo Á, Caridi F, Gonzalez-Magaldi M, Saiz J, Sobrino F, Martín-Acebes MA. The Amino Acid Substitution Q65H in the 2C Protein of Swine Vesicular Disease Virus Confers Resistance to Golgi Disrupting Drugs. Frontiers in Microbiology. 2016. DOI: https://doi.org/10.3389/fmicb.2016.00612

[11] Martino TA, Martino TA, Petric M, Weingartl H, Bergelson J, Opavsky M, et al.. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus.. Virology. 2000. DOI: https://doi.org/10.1006/VIRO.2000.0324

[12] Nielsen SC, Bruhn CAW, Samaniego JA, Wadsworth J, Knowles N, Gilbert M. Near-Complete Genome Sequencing of Swine Vesicular Disease Virus Using the Roche GS FLX Sequencing Platform. PLoS ONE. 2014. DOI: https://doi.org/10.1371/journal.pone.0097180

[13] Nassuato C, Boender G, Eblé P, Alborali L, Bellini S, Hagenaars T. Spatial Transmission of Swine Vesicular Disease Virus in the 2006–2007 Epidemic in Lombardy. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0062878

[14] Shirai J, Kanno T, Inoue T, Mitsubayashi S, Seki R. Effects of quaternary ammonium compounds with 0.1% sodium hydroxide on swine vesicular disease virus.. Journal of Veterinary Medical Science. 1997. DOI: https://doi.org/10.1292/JVMS.59.323

[15] Pezzoni G, Benedetti D, Bregoli A, Barbieri I, Foglia E, Grazioli S, et al.. Diagnostic Performances of Different Genome Amplification Assays for the Detection of Swine Vesicular Disease Virus in Relation to Genomic Lineages That Circulated in Italy. Viruses. 2020. DOI: https://doi.org/10.3390/v12111336

[16] Senthilkumaran C, Bittner H, Ambagala A, Lung O, Babiuk S, Yang M, et al.. Use of Oral Fluids for Detection of Virus and Antibodies in Pigs Infected with Swine Vesicular Disease Virus. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12563

[17] Yang M, Gagliardi K, McIntyre L, Xu W, Goolia M, Ambagala TC, et al.. Development and evaluation of swine vesicular disease isotype-specific antibody ELISAs based on recombinant virus-like particles.. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13363

[18] Xu W, Goolia M, Salo T, Zhang Z, Yang M. Generation, characterization, and application in serodiagnosis of recombinant swine vesicular disease virus-like particles. Journal of Veterinary Sciences. 2017. DOI: https://doi.org/10.4142/jvs.2017.18.S1.361

[19] Ko Y, Choi K, Nah J, Paton D, Oem J, Wilsden G, et al.. Noninfectious Virus-Like Particle Antigen for Detection of Swine Vesicular Disease Virus Antibodies in Pigs by Enzyme-Linked Immunosorbent Assay. Clinical Diagnostic Laboratory Immunology. 2005. DOI: https://doi.org/10.1128/CDLI.12.8.922-929.2005

[20] Monlux W, Graves J, McKercher PD. Brain and spinal cord lesions in pigs inoculated with swine vesicular disease virus (Hong Kong strain).. American Journal of Veterinary Research. 1974. DOI: https://doi.org/10.2460/ajvr.1974.35.05.615

[21] Kristensen T, Belsham G, Tjørnehøj K. Heat inactivation of foot-and-mouth disease virus, swine vesicular disease virus and classical swine fever virus when air-dried on plastic and glass surfaces. Biosafety and Health. 2021. DOI: https://doi.org/10.1016/j.bsheal.2021.07.002

[22] Morozov I, Monath T, Meekins D, Trujillo J, Sunwoo S, Urbaniak K, et al.. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Emerging Microbes and Infections. 2021. DOI: https://doi.org/10.1080/22221751.2021.1903343

[23] Shanzhen P, Wang Y, Yang Z, Yao X, Hu L, Chen P, et al.. A Double Polymerase Chain Reaction Method for Detecting African Swine Fever and Swine Vesicular Disease Virus. Tropical Journal of Pharmaceutical Research. 2015. DOI: https://doi.org/10.4314/TJPR.V14I5.16

[24] Paprocka G, Kęsy A. Real-time replication of swine vesicular disease virus (SVDV) in cell culture systems in vitro. Bulletin of the Veterinary Institute in Pulawy. 2015. DOI: https://doi.org/10.1515/BVIP-2015-0067

[25] Zhang T, Lu B, Yang B, Zhang D, Shi X, Shen C, et al.. Component Identification and Analysis of Vesicular Fluid From Swine Infected by Foot-and-Mouth Disease Virus. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2022.860978